IONIS PHARMACEUTICALS INC
IONS · XNASCIK 874015fmd_0V7467XKTX0RQQWQMBD2SP614EManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2008 to Sep 30, 2026, 71 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 373 | 514 | 600 | 1,123 | 729 | 810 | 587 | 788 | 705 | 944 |
| Cost of revenue | 0 | 0 | 2 | 4 | 12 | 11 | 14 | 9 | 11 | 16 |
| Realized investment gains (losses) | – | – | (0) | 0 | 17 | 1 | (0) | (2) | (3) | 9 |
| Gross profit | 373 | 514 | 598 | 1,118 | 717 | 800 | 573 | 779 | 694 | 928 |
| Research and development | 340 | 373 | 412 | 462 | 531 | 638 | – | 900 | 902 | 916 |
| Selling, general and administrative | 49 | 108 | 245 | 287 | 354 | 186 | 150 | 233 | 267 | 394 |
| Total operating expenses | 393 | 483 | 661 | – | – | – | – | – | – | – |
| Operating income | (20) | 31 | (61) | 366 | (172) | (30) | (410) | (354) | (475) | (382) |
| Interest expense | 39 | 45 | 45 | 12 | 10 | 9 | 8 | 13 | 17 | 17 |
| Other non-operating income (expense) | 0 | (4) | (0) | (1) | (0) | (10) | (7) | 14 | 1 | (15) |
| Income before taxes | (57) | (17) | (76) | 339 | (135) | (29) | (258) | (334) | (460) | (380) |
| Income tax expense | 3 | (6) | (291) | 52 | 345 | (1) | 12 | 32 | (6) | 2 |
| Net income from continuing operations | (60) | (11) | 215 | 287 | (480) | (29) | (270) | (366) | (454) | (381) |
| Net income | (60) | 0 | 274 | 278 | (444) | (29) | (270) | (366) | (454) | (381) |
| Net income to common shareholders | – | 19 | 277 | 281 | (444) | – | – | – | – | – |